LONZA N

494.40 Fr.
0.12 %

Lonza is a Swiss company specializing in life sciences, providing products and services to the pharmaceutical, biotechnology, and agrochemical sectors.

Performance & Momentum

6 Months 6.90 %
1 Year 13.16 %
3 Years 9.57 %
5 Years 22.32 %

Strategic Analysis

Lonza occupies a position as a global life sciences specialist, with a model centered on contract manufacturing and high-value-added services for pharmaceutical and biotech laboratories. Its positioning is based on complex industrial capabilities, high regulatory requirements, and a diversified client base, making it a key player in the healthcare value chain without being directly exposed to the commercial risk of drugs.

Strengths
  • Recognized expertise in contract manufacturing and complex processes that are difficult to replicate
  • Exposure to structurally attractive markets such as biotechnology and pharmaceuticals
  • Global positioning with commercial relationships anchored in recurring and critical needs
Weaknesses
  • Cyclical visibility on certain client programs, with sensitivity to laboratories' investment arbitrage decisions
  • Weakened stock market track record, suggesting more cautious market expectations for growth and execution
Momentum

Momentum remains decent but without a clear sign of a sharp rebound, despite an underlying trend that has remained fragile in recent years. The profile is more that of a quality stock in a stabilization phase than a high-acceleration story, with strategic appeal mainly for a patient investor seeking a defensive, technology-driven healthcare player.

Similar stocks to LONZA N

Anantys Community

Be the first to share your analysis on LONZA N.

Take control
of your investments

Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.

  • Real-time multi-portfolio tracking
  • AI analysis of your positions
  • Counter your cognitive biases